UT Tyler graduate earns Fulbright fellowship to study pitcher plants in Switzerland
UT Tyler celebrating evolutionary biology with Darwin Day events
Conneen, who graduated this month from UT Tyler with a bachelor's degree in biology, will go to Switzerland study the microbial microcosms in pitcher plants, a type of carnivorous plant.
'We congratulate Colm, who is a prime example of the excellent students we have in biology who go on to do amazing things,' said UT Tyler College of Arts and Sciences dean Dr. Neil Gray. 'I also want to thank Dr. Joshua Banta for being a tremendous mentor and supporter.'
Banta is a professor of biology at UT Tyler who taught Conneen and worked as his undergraduate faculty research advisor during their research on modeling the ecological niche of the Texas crayfish.
'From the moment he sought me out to work on a computational biology project, he showed a deep curiosity and determination to grow as a scientist,' Banta said. 'Our job at UT Tyler is to nurture and encourage students, and nothing makes us happier than seeing a student take full advantage of that support and then soar.'
Conneen is planning to get his doctorate degree and wants to work in ecological research and network sciences in the academic or industrial sectors. To learn more about the fellowship he received to study abroad, visit the Fulbright U.S. Student Program online.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Verge
18 hours ago
- The Verge
Microplastics are everywhere — including in the air around plastic treaty negotiations
Thousands of delegates have descended upon Geneva this week for what's supposed to be the culmination of years of negotiations that, if successful, are supposed to end in a groundbreaking global plastics treaty. They might be breathing in the very thing they're trying to clean up as they negotiate. Greenpeace tested the air around the city just before the talks began this month and found a small amount of microplastics. It wasn't so much a rigorous study as it was a way to prove a point. Microplastics are turning up all over the place, including in the air we breathe. That's why health and environmental advocates, as well as a coalition of governments, are pushing for an ambitious plastics treaty in Geneva. Recycling isn't enough — only limiting production can stem the tide of plastic pollution, they contend. Recycling isn't enough 'That you can find microplastics in urban air, that's not really shocking because it's been reported before in other cities. I think this is just a way of illustrating that nowhere is free from this pollution,' says David Santillo, a senior scientist with Greenpeace Research Laboratories. Greenpeace strapped an air-monitoring device to a person while they went about their day in Geneva, spending about eight hours in and out of shops, cafes, office spaces, and a railway station. The samples they collected on July 17th were meant to show what a typical visitor to the city might be exposed to; they weren't able to take any samples within the negotiation rooms that delegates would actually use. The device had a replaceable silver filter that Greenpeace researchers were then able to analyze to see what particles they caught, which amounted to at least 165 fibers and fragments. The filters picked up a range of different materials like bits of skin, plant-based fibers, and what was likely soot. Greenpeace was interested in synthetic materials, however, and was ultimately able to identify 12 pieces of microplastics, including polyester, nylon, polyethylene used to make bottles and bags, and other types of plastics. That might not sound like much, but the organization only had the equipment to be able to detect larger particles that were at least 10 microns in size. (For comparison, the average human hair is about 70 microns in diameter.) 'If they found the big ones, it's a pretty fair bet that the smaller ones were there, as well,' says Philip Landrigan, director of the Global Public Health and the Common Good Program at Boston College, who was not involved in the Greenpeace study. Generally, the smaller the particle, the more problems it can potentially pose by being able to penetrate deeper into organs and tissues in the human body. A human brain might contain as much as a spoon's worth of microplastics, research published in the journal Nature Medicine earlier this year suggests. 'Unfortunately, microplastics are pretty much everywhere in today's world,' Landrigan says. He's the lead author of an August report, published in the journal The Lancet, on the links between plastic pollution and health outcomes. 'Plastics cause disease and death from infancy to old age,' the report says, adding that plastics are responsible for $1.5 trillion in health-related economic losses each year. The report accounts for all the risks along the lifecycle of plastic, including chemicals that workers and communities near manufacturing facilities are exposed to, and waste that breaks down into nanoplastic particles that have been found in human bodies and breastmilk. 'Plastics cause disease and death from infancy to old age' Scientists are still working to understand the health impacts of inhaling microplastics in the air. Landrigan points out that we at least know that all plastics are made of two main components, a carbon-based backbone derived from fossil fuels and chemical additives. 'When the microplastic comes into the human body, whether you inhale it or drink it with your water or eat it with your food, when it it gets into you and the plastics move from your gastrointestinal tract into the bloodstream, the microplastic particles are carrying all those chemicals with them,' Landrigan says. The more than 16,000 different chemicals used in plastics production — including the carcinogen vinyl chloride, for example — are primarily responsible for the known health risks associated with plastics. But the toxicity of more than 75 percent of the chemicals in plastics have yet to be studied. Greenpeace doesn't claim to be assessing air quality in Geneva or the health impacts of what they found in their air samples. All they can show is the presence of microplastics in the air, adding to previous research that has done the same. What's notable now is that Greenpeace has documented this at a time when leaders from around the world have the opportunity to actually do something about it. Negotiations on a plastics treaty in Geneva are scheduled to end on August 14th. In 2022, United Nations member states agreed to develop a legally binding pact on plastic pollution. It's been an uphill battle to agree on terms ever since. Major fossil fuel producing nations blocked a deal in December, pushing negotiations past their initial 2024 deadline. So far this year, there's still a fight over whether focusing on recycling and reducing plastic waste is enough. The fossil fuel industry and countries including the US that produce a lot of plastics and its ingredients are fighting efforts to exclude limits to plastic production from the treaty. A 'high ambition coalition' launched by Rwanda and Norway, on the other hand, wants to address the full lifecycle of plastic, starting with production. It's also open to using the treaty to phase out or restrict the use of problematic chemicals in plastics. It doesn't make sense to simply mop up the mess plastic leaves behind without also turning off the faucet, says Angel Pago, Greenpeace global plastics campaign media lead. 'We're brimming with plastic because of overproduction. And we cannot solve this crisis with just, you know, cleanups,' Pago tells The Verge from Geneva. The Lancet article similarly says 'the principal driver of this [health] crisis is accelerating growth in plastic production.' Production has ballooned from 2 metric megatons in 1950 to 475 in 2022. Less than 10 percent of plastic waste has ever been recycled, in part because the many chemicals used to manufacture different types plastics make it difficult or uneconomical to rehash the material. 'If we're going to do something about plastics, we need to cap plastic production,' Landrigan says. 'I hope and I pray that the treaty negotiators are actually going to produce a treaty that protects human health.' Posts from this author will be added to your daily email digest and your homepage feed. See All by Justine Calma Posts from this topic will be added to your daily email digest and your homepage feed. See All Climate Posts from this topic will be added to your daily email digest and your homepage feed. See All Environment Posts from this topic will be added to your daily email digest and your homepage feed. See All Health Posts from this topic will be added to your daily email digest and your homepage feed. See All Policy Posts from this topic will be added to your daily email digest and your homepage feed. See All Report Posts from this topic will be added to your daily email digest and your homepage feed. See All Science
Yahoo
a day ago
- Yahoo
Swiss pilot surpasses solar-powered plane altitude record
Swiss pilot Raphael Domjan beat the altitude record for a solar-powered electric plane in a flight that took him soaring to 9,521 metres, his team announced Wednesday. The SolarStratos plane made the landmark flight from Sion airport in southwest Switzerland on Tuesday, taking advantage of warm air thermals to go beyond the 15-year-old record. The certified altitude record for a solar plane had stood at 9,235 metres (30,298 feet). It was set in 2010 by the Solar Impulse plane, with Swiss pilot Andre Borschberg at the controls. Domjan's flight lasted five hours and nine minutes. "I share this moment of joy with all the people who have been preparing for this achievement for years," he said, celebrating afterwards with the melted cheese of a traditional Swiss raclette. The data will be sent to the World Air Sports Federation governing body, which will decide whether to validate the new record. "It is the pressure altitude corrected to standard density altitude that is recognised as the official reference for aviation altitude records," the SolarStratos team said in a statement. Domjan is aiming to be the first to take a solar-powered plane above 10,000 metres -- flying at the same altitude as airliners. If this barrier is broken, the team hopes to go on and make a first manned solar-powered flight into the stratosphere, which at Switzerland's latitude begins at around 12,000 metres. "This achievement marks a major milestone on the path toward reaching the stratosphere using only solar power -- and already fulfils the mission's goal: to capture imaginations with emblematic, spectacular challenges that promote solar energy and the protection of our biosphere and planet," SolarStratos said. rjm/vog/tw
Associated Press
2 days ago
- Associated Press
Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) ('Oculis'), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs, today announced that Oculis' management will be participating in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. Links to access the corporate update presentation and the panel discussion will be posted to Oculis' website on the Events & Presentation page under the Investors & Media section. About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs. Oculis' highly differentiated late-stage clinical pipeline includes three core product candidates: OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate in Phase 2 for acute optic neuritis, with potentially broad clinical applications in various neuro-ophthalmic and neurological diseases; and Licaminlimab (OCS-02), a novel topical anti-TNFα in Phase 2, being developed with a genotype-based approach to drive personalized medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. For more information, please visit: Oculis Contacts Ms. Sylvia Cheung, CFO [email protected] Investor Relations LifeSci Advisors Corey Davis, Ph.D. [email protected] Media Relations ICR Healthcare Amber Fennell / David Daley / Sean Leous [email protected]
